Mastocytosis Clinical Trials 2023

What are the top hospitals conducting mastocytosis research?

When it comes to cutting-edge clinical trials in the realm of mastocytosis, several top hospitals across the United States are leading the way. In Boston, Dana Farber Cancer Institute is at the forefront with four active trials focused on this rare condition characterized by an abnormal accumulation of mast cells in various organs. With a total of eight recorded mastocytosis trials since their initial investigation began in 2005, Dana Farber has been committed to advancing our understanding and treatment options for patients affected by this complex disorder.

Meanwhile, Washington University School of Medicine in Saint Louis joined the research efforts more recently but demonstrates promising dedication with three ongoing mastocytosis trials since recording their first trial in 2018. Located on the West Coast, Stanford Cancer Institute has also made significant contributions, currently conducting three active clinical trials for mastocytosis while building upon four previous studies initiated since 2016.

In Chicago's Rush University Medical Center and Minnesota's renowned Mayo Clinic located in Rochester similarly demonstrate their commitment through simultaneous participation delivering valuable insight through three on-going investigations respectively having started its study as recent as just few years ago backin 2018 & like others dedicatedly continuing furthering knowledgebase around Mastocystitis

These leading hospitals represent not only hope for individuals living with mastocytosis but also highlight how medical progress can be achieved when experts collaborate and focus their efforts towards solving these challenging conditions. Through innovative clinical trials conducted across multiple locations nationwide we move ever closer toward effective treatments that could transform lives impacted by this uncommon yet debilitating disease

Which are the best cities for mastocytosis clinical trials?

When it comes to mastocytosis clinical trials, several cities have emerged as key players in advancing research and treatment options. Boston, Massachusetts leads the way with 8 active trials focusing on Avapritinib, Bezuclastinib, MGD024, and other promising interventions. Saint Louis, Missouri follows closely behind with 5 ongoing studies investigating MGD024, Avapritinib, Bezuclastinib Dose 1 + BSC, and other potential breakthroughs. Houston, Texas also demonstrates its commitment to mastocytosis research with 5 active trials exploring Avapritinib, Bezuclastinib Dose 1 + BSC, bezuclastinib, and more. Rochester, Minnesota contributes significantly to the field as well through its participation in 5 trials examining various treatments such as BLU-263 and topical preparations of sodium cromolyn. Lastly but no less important is Ann Arbor Michigan where researchers conduct four clinical trials focused on Avapritinib and Bezuclastinib among others. These cities offer individuals living with mastocytosis access to cutting-edge clinical studies that hold promise for improved management of this condition.

Which are the top treatments for mastocytosis being explored in clinical trials?

Exciting advancements in mastocytosis research are underway, with several promising treatments currently being explored in clinical trials. Avapritinib takes the lead, with two active trials and a total of three mastocytosis trials since its introduction in 2016. Following closely behind is MGD024, showing great potential with one ongoing trial and marking its debut on the scene in 2022. Additionally, bezuclastinib and BLU-263 both show promise as they each have one active trial under their belt and have been listed since 2021. These innovative therapies offer hope for patients battling mastocytosis by targeting specific pathways implicated in the disease's progression.

What are the most recent clinical trials for mastocytosis?

Exciting advancements are underway in the realm of mastocytosis, as recent clinical trials offer new possibilities for treatment. Amongst them is MGD024, a phase 1 trial that holds promise for individuals with this condition. Additionally, bezuclastinib has shown potential in both phase 2 and part 1b studies when combined with best supportive care (BSC). Another noteworthy trial involves BLU-263, which has progressed to phases 2 and 3. Furthermore, topical preparations containing sodium cromolyn, diphenhydramine, and trolamine salicylate have been explored through a phase 2 study. These ongoing investigations aim to improve management strategies and provide hope for those affected by mastocytosis.

What mastocytosis clinical trials were recently completed?

Recently, a clinical trial for mastocytosis investigated the potential of DCC-2618, sponsored by Deciphera Pharmaceuticals LLC. This trial was completed in October 2015 and represents an important step forward in our understanding and treatment of this complex condition. The results from this study are expected to provide valuable insights into the efficacy and safety profile of DCC-2618 for patients with mastocytosis.